Клинически незначимый рак предстательной железы: современная тактика выбора терапии

Клинически незначимый рак предстательной железы: современная тактика выбора терапии

Автор: Дарий Е.В., Бедретдинова Д.А., Гарманова Т.Н.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Рак предстательной железы, рак почки

Статья в выпуске: 1, 2012 года.

Бесплатный доступ

Рак предстательной железы, динамическое наблюдение, клинически незначимый рак предстательной железы, скрининг, пса, биопсия

Короткий адрес: https://sciup.org/142188291

IDR: 142188291

Список литературы Клинически незначимый рак предстательной железы: современная тактика выбора терапии

  • Аполихин О.И., Сивков А.В., Бешлиев Д.А., Солнцева Т.В., Комарова В.А., Зайцевская Е.В. Анализ урологической заболеваемости в Российской Федерации в 20022009 годах по данным официальной статистики//Экспериментальная и клиническая урология. 2011. № 1. С. 4-10.
  • Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009//CA Cancer J Clin. 2009. Vol. 59. P. 225-249.
  • Ferlay J., Autier P., Boniol M. Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006//Ann Oncol. 2007. Vol. 18. P. 581-592.
  • Sakr W.A., Grignon D.J., Crissman J.D., Heilbrun L.K., Cassin B.J., Pontes J.J., Haas G.P. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases//In Vivo. 1994. Vol. 8. P. 439-443.
  • Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer//JAMA. 1994. Vol. 271. P. 368-374.
  • Yatani R., Chigusa I., Akazaki K., Stemmermann G.N., Welsh R.A., Correa P. Geographic pathology of latent prostatic carcinoma//Int J Cancer. 1982. Vol. 29. P. 611-616.
  • Johansson J.E., Andren O., Andersson S.O., Dickman P.W., Holmberg L., Magnuson A., Adami H.O. Natural history of early, localized prostate cancer//JAMA. 2004. Vol. 291. P. 2713-2719.
  • Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., Feuer E.J. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends//J Natl Cancer Inst. 2002. Vol. 94. P. 981-990.
  • Catalona W.J., Partin A.W., Slawin K.M., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., de Kernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N., Parson R.E., Gasior G.H., Loveland K.G., Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial//JAMA. 1998. Vol. 279. P. 1542-1547.
  • D’Amico A.V., Chen M.H., Roehl K.A., Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy//N Engl J Med. 2004. Vol. 351. P. 125-135.
  • Heidenreich A., Aus G., Bolla M., Joniau S., Matveev V.B., Schmid H.P., Zattoni F. European Associatio. EAU guidelines on prostate cancer//Eur Urol. 2008. Vol. 53. P. 68-80.
  • Schroder F.H., Carter H.B., Wolters T., van den Bergh R.C., Gosselaar C., Bangma C.H., Roobol M.J. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics//Eur Urol. 2008. Vol. 53. P. 468-477.
  • Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I., Partin A.W. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005//Urology. 2007. Vol. 69. P. 1095-1101.
  • Heidenreich A., Aus G., Bolla M., Joniau S., Matveev V.B., Schmid H.P., Zattoni F. European Association of Urology. [EAU guidelines on prostate cancer]//Actas Urol Esp. 2009. Vol. 33. P. 113-126.
  • Sanda M.G., Dunn R.L., Michalski J., Sandler H.M., Northouse L., Hembroff L., Lin X., Greenfield T.K., Litwin M.S., Saigal C.S. Quality of life and satisfaction with outcome among prostate-cancer survivors//N Engl J Med. 2008. Vol. 358. P. 1250-1261.
  • Dall’Era M.A., Cooperberg M.R., Chan J.M., Davies B.J., Albertsen P.C., Klotz L.H., Warlick C.A., Holmberg L., Bailey D.E. Jr., Wallace M.E., Kantoff P.W., Carroll P.R. Active surveillance for early-stage prostate cancer: review of the current literature//Cancer. 2008. Vol. 112. P. 1650-1659.
  • Epstein J.I. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection//Semin Oncol. 1994. Vol. 21. P. 527-541.
  • Kattan M.W., Eastham J.A., Wheeler T.M., Maru N., Scardino P.T., Erbersdobler A., Graefen M., Huland H., Koh H., Shariat S.F., Slawin K.M., Ohori M. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors//J Urol. 2003. Vol. 170. P. 1792-1797.
  • Patel M.I., DeConcini D.T., Lopez-Corona E., Ohori M., Wheeler T., Scardino P.T. An analysis of men with clinically localized prostate cancer who deferred definitive therapy//J Urol. 2004. Vol. 171. P. 1520-1524.
  • Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management//J Clin Oncol. 2004. Vol. 22. P. 2141-2149.
  • Draisma G., Boer R., Otto S.J., van der Cruijsen I.W., Damhuis R.A, Schröder F.H., de Koning H.J. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer//J Natl Cancer Inst. 2003. Vol. 95. P. 868-878.
  • Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer//JAMA. 2005. Vol. 293. P. 2095-2101.
  • Johansson J.E., Adami H.O., Andersson S.O., Bergström R., Krusemo U.B., Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients//Lancet. 1989. Vol. 1. P. 799-803.
  • Capitanio U., Jeldres C., Shariat S.F., Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best//Eur Urol. 2008. Vol. 54. P. 958-959.
  • D’Amico A.V., Cote K., Loffredo M., Renshaw A.A., Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer//J Clin Oncol. 2002. Vol. 20. P. 4567-4573.
  • Chun F.K., Haese A., Ahyai S.A., Walz J., Suardi N., Capitanio U., Graefen M., Erbersdobler A., Huland H., Karakiewicz P.I. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men//Cancer. 2008. Vol. 113. P. 701-709.
  • Schroder F., Kattan M.W. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review//Eur Urol. 2008. Vol. 54. P. 274-290.
  • Carter H.B., Kettermann A., Warlick C., Metter E.J., Landis P., Walsh P.C., Epstein J.I. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience//J Urol. 2007. Vol. 178. P. 2359-2364; discussion 2364-2355.
  • Klotz L. Active surveillance for prostate cancer: for whom?//J Clin Oncol. 2005. Vol. 23. P. 8165-8169.
  • Carter H.B., Ferrucci L., Kettermann A., Landis P., Wright E.J., Epstein J.I., Trock B.J., Metter E.J. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability//J Natl Cancer Inst. 2006. Vol. 98. P. 1521-1527.
  • Freedland S.J., Humphreys E.B., Mangold L.A., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., Partin A.W. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy//JAMA. 2005. Vol. 294. P. 433-439.
  • Khatami A., Aus G., Damber J.E., Lilja H., Lodding P., Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section//Int J Cancer. 2007. Vol. 120. P. 170-174.
  • Choo R., Klotz L., Danjoux C., Morton G.C., De Boer G., Szumacher E., Fleshner N., Bunting P., Hruby G. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression//J Urol. 2002. Vol. 167. P. 1664-1669.
  • Ercole B., Marietti S.R., Fine J., Albertsen P.C. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era//J Urol. 2008. Vol. 180. P. 1336-1339; discussion 1340-1331.
  • Hardie C., Parker C., Norman A., Eeles R., Horwich A., Huddart R., Dearnaley D. Early outcomes of active surveillance for localized prostate cancer//BJU Int. 2005. Vol. 95. P. 956-960.
  • Roemeling S., Roobol M.J., de Vries S.H., Wolters T., Gosselaar C., van Leenders G.J., Schröder F.H. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome//Eur Urol. 2007. Vol. 51. P. 1244-1250; discussion 1251.
  • Soloway M.S., Soloway C.T., Williams S., Ayyathurai R., Kava B., Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience//BJU Int. 2008. Vol. 101. P. 165-169.
  • van As N.J., Norman A.R., Thomas K., Khoo V.S., Thompson A., Huddart R.A., Hor-wich A., Dearnaley D.P., Parker C.C. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance//Eur Urol. 2008. Vol. 54. P. 1297-1305.
  • Warlick C., Trock B.J., Landis P., Epstein J.I., Carter H.B. Delayed versus immediate surgical intervention and prostate cancer outcome//J Natl Cancer Inst. 2006. Vol. 98. P. 355357.
  • Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer//Urol Oncol. 2006. Vol. 24. P. 46-50.
  • Freedland S.J., Kane C.J., Amling C.L., Aronson W.J., Presti J.C. Jr., Terris M.K.; SEARCH Database Study Group. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer//J Urol. 2006. Vol. 175. P. 1298-1302.
  • Litwin M.S., Lubeck D.P., Spitalny G.M., Henning J.M., Carroll P.R. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor//Cancer. 2002. Vol. 95. P. 54-60.
  • Fritzsche K., Diederich D., Schultze-Seemann W. [Psychooncology of prostate carcinoma -psychosocial distress and treatment approaches: a systematic review]//Z Psychosom Med Psychother. 2008. Vol. 54. P. 329-353.
  • Bailey D.E. Jr., Wallace M., Mishel M.H. Watching, waiting and uncertainty in prostate cancer//J Clin Nurs. 2007. Vol. 16. P. 734-741.
  • Galbraith M.E., Ramirez J.M., Pedro L.W. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups//Oncol Nurs Forum. 2001. Vol. 28. P. 551-560.
  • Hedestig O., Sandman P.O., Widmark A. Living with untreated localized prostate cancer: a qualitative analysis of patient narratives//Cancer Nurs. 2003. Vol. 26. P. 55-60.
  • Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer//Oncol Nurs Forum. 2003. Vol. 30. P. 303-309.
  • Steineck G., Helgesen F., Adolfsson J., Dickman P.W., Johansson J.E., Norlén B.J., Holmberg L.; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting//N Engl J Med. 2002. Vol. 347. P. 790-796.
  • Latini D.M., Hart S.L., Knight S.J., Cowan J.E., Ross P.L., Duchane J., Carroll P.R. CaPSURE Investigators. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance//J Urol. 2007. Vol. 178. P. 826-831.
  • Pickles T., Ruether J.D., Weir L., Carlson L., Jakulj F.; SCRN Communication Team. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance//BJU Int. 2007. Vol. 100. P. 544-551.
  • Barocas D.A., Cowan J.E., Smith J.A. Jr., Carroll P.R. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database//J Urol. 2008. Vol. 180. P. 1330-1334.
  • Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism//Annu Rev Pharmacol Toxicol. 2005. Vol. 45. P. 629-656.
  • Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., Schüle R., Buettner R. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence//Cancer Res. 2006. Vol. 66. P. 11341-11347.
  • Luo J., Zha S., Gage W.R., Dunn T.A., Hicks J.L., Bennett C.J., Ewing C.M., Platz E.A., Ferdinandusse S., Wanders R.J., Trent J.M., Isaacs W.B., De Marzo A.M. Alpha-methylacyl-CoA race-mase: a new molecular marker for prostate cancer//Cancer Res. 2002. Vol. 62. P. 2220-2226.
  • Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer//N Engl J Med. 2003. Vol. 349. P. 366-381.
  • Arlen P.M., Mohebtash M., Madan R.A., Gulley J.L. Promising novel immunotherapies and combinations for prostate cancer//Future Oncol. 2009. Vol. 5. P. 187-196.
  • Bastian P.J., Carter B.H., Bjartell A., Seitz M., Stanislaus P., Montorsi F., Stief C.G., Schröder F. Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications//Eur Urol. 2009. Vol. P. 1321-1330.
Еще
Статья
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp